Plasma phenylethylamine in schizophrenic patients.
Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic patients compared with controls. There were no differences in PE between paranoid and nonparanoid patients. Plasma PE did not appear to be influenced by the severity of schizophrenic symptoms (rated by BPRS, SANS, and SAPS) or by the amount of dietary phenylalanine ingested within 24 hr of testing. Plasma PE did not correlate with current or past exposure to neuroleptic medication. It was not possible, however, to test individual patients during two periods when they were taking and not taking medication. Thus it is possible that neuroleptic exposure may have confounded the results. This study provides further evidence that PE excess may play a role in the etiology of schizophrenia but does not support previous studies which suggest that such an abnormality is limited to the paranoid subgroup.
O'Reilly
R
R
Department of Psychiatry, St. Thomas Psychiatric Hospital, Ontario, Canada.
Davis
B A
BA
Durden
D A
DA
Thorpe
L
L
Machnee
H
H
Boulton
A A
AA
D000328:Adult; D000367:Age Factors; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D010627:Phenethylamines / Q000097:blood*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000097:blood* / Q000175:diagnosis; D012565:Schizophrenic Psychology; D012737:Sex Factors
D010627:Phenethylamines; C029261:phenethylamine